Nanobiotix S.A. files 20-F

Nanobiotix S.A. reported a net loss of €23.961 million for the fiscal year ended December 31, 2025, a significant improvement from the €68.132 million net loss in 2024, primarily due to a one-time positive revenue impact of €21.8 million from an amendment to its licensing agreement with Janssen. The company also secured a royalty financing agreement with HCRx for up to $71 million, with an initial $50 million received in December 2025, and completed the transfer of global sponsorship for its pivotal NANORAY-312 clinical trial to Janssen. (2) Key-point bullets: